We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 103.00 | 102.00 | 104.00 | 103.00 | 103.00 | 103.00 | 25,020 | 08:00:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
TIDMDXRX
RNS Number : 8460H
Diaceutics PLC
29 November 2022
29 November 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Change of Auditor
Diaceutics PLC , ( AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the Precision Medicine market announces that, following the conclusion of a formal tender process led by the Company's Audit Committee, the Board has approved the proposed appointment of Ernst & Young ("EY") as the Company's auditor for the financial year ending 31 December 2022. A proposal to re-appoint EY will be subject to approval by the Company's shareholders at the next Annual General Meeting to be held in 2023.
PricewaterhouseCoopers LLP, the Company's current auditor, has resigned and has confirmed that there are no matters connected with it ceasing to hold office that should be brought to the attention of the members or creditors of the Company.
Enquiries:
Diaceutics PLC Nick Roberts, Chief Financial Officer Via Alma PR Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600 Ben Maddison Stewart Wallace Nick Adams Alma PR Tel: +44(0)20 3405 0205 Caroline Forde diaceutics@almapr.co.uk Kieran Breheny Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPBKFBKCBDDQDB
(END) Dow Jones Newswires
November 29, 2022 02:00 ET (07:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions